These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25891210)

  • 21. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　- ODYSSEY JAPAN Randomized Controlled Trial.
    Teramoto T; Kobayashi M; Tasaki H; Yagyu H; Higashikata T; Takagi Y; Uno K; Baccara-Dinet MT; Nohara A
    Circ J; 2016 Aug; 80(9):1980-7. PubMed ID: 27452202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy of pitavastatin versus simvastatin.
    Eriksson M; Budinski D; Hounslow N
    Adv Ther; 2011 Sep; 28(9):799-810. PubMed ID: 21874537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia.
    Ose L; Budinski D; Hounslow N; Arneson V
    Curr Med Res Opin; 2009 Nov; 25(11):2755-64. PubMed ID: 19785568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
    Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
    Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
    Stender S; Budinski D; Gosho M; Hounslow N
    Eur J Prev Cardiol; 2013 Feb; 20(1):40-53. PubMed ID: 22679249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
    Stender S; Budinski D; Hounslow N
    Eur J Prev Cardiol; 2013 Feb; 20(1):29-39. PubMed ID: 22345687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
    Yee LL; Wright EA
    Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
    J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
    Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
    PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia.
    Miller PE; Martin SS; Joshi PH; Jones SR; Massaro JM; D'Agostino RB; Sponseller CA; Toth PP
    Clin Ther; 2016 Mar; 38(3):603-9. PubMed ID: 26922296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
    Yokote K; Bujo H; Hanaoka H; Shinomiya M; Mikami K; Miyashita Y; Nishikawa T; Kodama T; Tada N; Saito Y
    Atherosclerosis; 2008 Dec; 201(2):345-52. PubMed ID: 18472103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
    Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
    Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Arai H; Teramoto T; Daida H; Ikewaki K; Maeda Y; Nakagomi M; Shirakawa M; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Vaidya S; Blaustein RO
    Atherosclerosis; 2016 Jun; 249():215-23. PubMed ID: 27131642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
    Barrios V; Escobar C; Zamorano JL
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
    Davidson M
    Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
    Duggan ST
    Drugs; 2012 Mar; 72(4):565-84. PubMed ID: 22356292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.